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The protein kinasc C (PKC) family participates in a ubiquitous ccl1 signallinS system utilizing increased turnover of’ phosphoinositides. Because 
down-regulation or total PKC activity has been implicated in the acquisition of a morphologically differentiated phenotype in SH-SYSY ncuro- 
blastoma cells, we aimed to identify the specific PKC isoforms in this process. Here we report that intracellular delivery of PKC-a and -e, but not 
-p,, -y or -S ieolbrm-specific antibodies is sufficient o induce acquisition of a morphologically differentiated phenotype in SH-SYTY ncuroblastoma 
ceils. 
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1. INTRODUCTION 
Our understanding of the complexity of intracellular 
signal transduction pathways has been increased greatly 
in the recent years by the discovery of eight isoforms of 
protein kinase C (PIE) [l-7], a phospholipid-depend- 
ent serine/threonine kinase [8] that constitutes one ofthe 
arms of the bifurcating signalling system involving en- 
hanced phosphoinositide turnover [9]. PKC isoforms 
differ in their sensitivity to activators and inhibitors 
[ l,lO, 1 I] and have discrete subcellular distribution and 
tissue specific expression Cl]. The a, p,, p,, and y isoforms 
are Ca”‘-dependent [l], but the newly described sub- 
species 6, E, (0 and q/L are Ca?‘-insensitive 
[2,6,7,10-l 11. Because the diversity in the PKC family 
suggests pecialization, it has been proposed that the 
different PKC isoforms may be involved in discrete cel- 
lular functions [1,3]. In addition, it is well documented 
that PKC can be down-regulated through an increase 
in proteolysis [l&133. However, the biological im- 
portance of this phenomenon is unclear. 
Neuroblastoma cells in culture are a model of neu- 
ronal differentiation [14,15]. The purely neuroblastic 
adrenergic subclone SH-SYSY [la] extends neurites and 
expresses neuronal markers when treated for prolonged 
periods of time with the co-carcinogenic phorbol ester 
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TPA [ 17,l S] and early after exposure to PKC inhibitors 
such as staurosporine [19]. Differentiation of SM-SYTY 
cells induced by TPA is almost complete [ 151, involving 
down-regulation of the expression of c-n?yc and increase 
of the expression of c-fos [20], followed by appearance 
of voltage-dependent Ca?‘-channels [21], neuron-spe- 
cific enolase [18,21], norepinephrine [22], and neurites 
[IS], containing stable cytoskeleton [23]. 
A decrease in PKC activity has been proposed to be 
a triggering event in neuritogenesis in SH-SYSY neuro- 
blastoma cells [17]. Thus PKC inhibitors uch as stauro- 
sporine or H-7 induce extension of neurites [17,191, and 
treatment with TPA, sufficient o induce down-regula- 
tion of the kinase, also results in neuritogenesis [17,24]. 
The processes induced by these treatments contain neu- 
rofilaments, microtubules and neuromediator vesicles 
(U. Leli et al., in preparation). 
We have previously demonstrated the pr sence in 
SH-SY SY cells of PKC-a, -b,, -7, -6 and E [24]. We have 
also reported differential down-regulation of the CI and 
e isoforms during SII- SYSY cell differentiation i duced 
by long-term exposure both to TPA or staurosporine 
[24]. The downregulation in PKC-a and -E expression 
could be a phenomenon secondary to differentiation. 
However, the fact that the inhibitor staurosporine also 
caused downregulation of the same PKC isoforms af- 
fected by prolonged TPA treatment, suggests that the 
decrease in PKC-a and -E could play an active role in 
the process of differentiation. In this study we 
attempted to explore this second t;yi;~it;tis 5;~ in?~- 
fering selectively with each isoform, using isoform-spe- 
cific antibodies delivered intracellularly. 
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2. EXPERIMENTAL 
SH-SYSY cells were obtained from Dr. June Bicdler (Memorial 
Sloan-Kettering Center, NY) and maintained in RPM1 1640 with 
t,-glutamine, containing 10% fetal bovine serum, 100 IU/ml penicillin 
and lOO~g/ml streptomycin, i  a 95%/5% (v/v) atmosphere ofair/CO, 
[ 171. For the permcabilization experiments dcscrilxd in this paper cells 
were grown in Lab-Tek @-chamber) culture slides (Nunc, Naperville, 
IL) to 75% confluency, and equilibrated for 24 h in the same medium 
containing 7% of fetal bovine serum before use. 
Polyclonal antibodies against synthetic peptides representing a vari- 
able region at the carboxyl-terminal of PKC(V5) were raised in rabbit 
and characterized as described ([I 1,25,26], and P.J.P., unpublished). 
Antibodies were introduced into SH-SYSY cells aider permexbiliza- 
tion with lysolecithin as described [27] with minor modifications. 
Briefly, after 24 h equilibration with 7% fetal bovine serum-containing 
medium, cultures were washed with serum-free medium and 100~1 of 
1.2 M glycerol in phosphate-buffered saline at 37OC was added. After 
6 min on ice, 4~1 of a I m&/ml lysolecithin (Sigma Chemical Co., St. 
Louis, MO) solution in water was added, and the incubation COII- 
tinued for an additional 5 minutes. Cells were then brought o 37’C 
and 100 ~1 of a dilution of antibody was added. After 10 additional 
minutes at 37OC, during which the cells reseal [27], IOO~I of medium 
containing 2 I % fetal bovine serum was added. This was called f,,. After 
30 min equilibration a change of medium was effected, and the cells 
brought back to the 7% serum-containing medium. Incubations were 
continued as indicated. At the end of the incubation cells were fixed 
and examined by phase-contrast microscopy [23]. When antibodies 
were pre-absorbed with antigen peptides, the pcptides in three-fold 
excess were mixed whh the antibodies at least 5 min before USC. For 
visualization of antibodies in the treated cultures, cells were immu- 
nostaincd with a secondary biotinylated goat anti-rabbit antibody, 
using the ABC system as described [23]. 
Extension of neurites was quantitated bycounting IOOBIO cells in 
ten random fields per culture, and scoring as positive the cells contain- 
ing one or more than one neurite, longer than the major cell body 
diameter [l9]. Values were expressed as neurile-bearing cells, as per- 
ccntagc of the total cells counted. Statistical analysis was performed 
using the two-tailed Student’s r-test. 
3. RESULTS AND DISCUSSION 
Because SH-SYSY cells contain at least five PKC 
isoforms (a, B,, y, 6 and &), and their expression is 
selectively down-regulated uring neuritogenesis [24], 
we asked which of these isoforms might be specifically 
implicated in the acquisition of a morphologically diffe- 
rentiated phenotype in these cells. No PKC isoform- 
specific inhibitor is available at present. Therefore, we 
approached the problem of dissecting which PKC 
isoform was involved in the acquisition of a mor- 
phologically differentiated phenotype in this cell line by 
interfering with the individual isoforms using antibod- 
ies. For this purpose we transiently permeabilized SH- 
SYSY cultures using lysolecithin [27] and introduced 
immunoprecipitating, isoform-specific antibodies 
against PKC-a, -p,, -y, -6 or -E [11,25,26]. 
In order to ensure that the antibodies were penetrat- 
ing the cells, we immunostained cultures with goat anti- 
rabbit secondary antibody coupled with horseradish 
peroxidase, which showed that the ceils were ffectiveiy 
permeabilized and loaded with antibody (Fig. 1). In 
agreement with our previous data [24], anti-PKC-a an- 
tibodies were detected immunocytochemically only at 
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Fig. I. Intracellular delivery of PKC-a-isoform-specific antibody. SH-
SYSY cells were penneabilized and loaded using lysolecithin and hy- 
perosmolar shock [27], in the presence of I:200 dilution ofanti-PKC-ct. 
The transmission light micrograph shows immunostaining with the 
antibody localized at the plasma membrane. 
the plasma membranes of treated ceils (Fig. 1). No im- 
munostaining in the cytoplasm was observed, as 
reported previously for SH-SYSY cells differentiated by 
treatment with either staurosporine or TPA [24]. 
Anti-PKC-a or -8, but not -p,, -y or -6 caused exten- 
sion of processes longer than the cell body starting at 
one hour of exposure and continuing through the third 
hour (Table I and Fig. 2). Simultaneous treatment with 
anti-PKC-a and -E produced an additive effect (Table 
I). Effective antibody dilution ranged from 1:200 (Table 
I and Fig. 2) to 1:2000, although they were less effective 
at these higher dilutions (not shown). In order to con- 
firm the specificity of these effects we pre-adsorbed the 
antibodies with the peptide antigens used to raise them. 
Pre-treatment of both PKC-a and PKC-E antibodies 
with an excess of their respective peptide antigens, de- 
creased the stimulatory effects on neurite extension to 
values not sta&Gcally different from the control (Table 
I). Treatment with the antigens alone did not cause any 
change in the number of neurite-bearing cells (Table I). 
With the protocol employed in these studies the 
effects of antigen binding on PKC-a and -e activities 
cannot be established. However, it seems probable that 
in inducing neuritogenesis the antibodies have a nega- 
tive effect on enzyme function, perhaps through in- 
creased breakdown of the antigen-antibody complex. 
This interpretation would be consistent with the 
observation that antisera to these C-terminal epitopes 
neither stimulate nor inhibit purified PKC isoforms in 
vitro (R, Marais and P.J.P., unpublished). This inferred 
loss of function would also be in agreement with 
published work showing selective decreases in the 
steady-state levels of mRNA for PKC-a and PKC-E in 
the mouse neuroblastoma cell line neuro-2a during dif- 
ferentiation induced by retinoic acid [28,29], with a 
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Fig. 2. Effects of PKC-isoform-specitic antibody loading on the morphology of SH-SYSY cells. SH-SYSY eells were grown, prmcabilized and 
loadud with A I:200 dilution of anti-PKC-P (panel a) or -E (panels b and c) as dcscribcd in section 2. Phase-contrast micrographs were taken after 
2 h. Neuritc-like processes arc indicated by arrowheads. Rcsuhs similar to panel a ivcrc obrained using anti-PKC;B,, -y and -&and similar to panel 
b using anti-PKC-a, or anti-PKC-r + anti-PKC-& (not shown), Panel c shows the cffccts ofprc-adsorption of anti-PKC-& with thc.+antigen pcptidc 
as dcscrifxd in TabIt I. 
report demonstrating that decreased activity of PKC 
caused by actinomycin D induced extension of neurites 
[30], and with studies supporting that decreased phos- 
phorylation is involved in neuritogenesis [31]. Further 
support to this view, that a decrease in the phosphoryl- 
ation of some protein substrate of PKC may be involved 
in neuritogenesis also comes from studies howing that 
a correlation exists between phosphorylation of some 
intermediate filament proteins such as vimentin, and 
disassembly of the intermediate filament network dur- 
ing cell cycle [32,33]. 
The results presented here represent a direct demon- 
stration that interference in the function of two specific 
PKC isoforms, PKC-a and PKC-6, is sufficient o in- 
duce neurite extension in SH-SYSY neuroblastoma 
cells. Differential roles of PKC-a and PKC-E in the 
acquisition of a differentiated phenotype in SH-SYSY 
cells are implied by the additive, rather than synergistic 
or mutually exclusive effects of anti-PKC-a and -E 
(Table I). This suggests that down-regulation of PKC-a 
and PKC-E may participate in separate steps of the 
process of neuroblastoma cell differentiation, in agree- 
ment with their different biochemical properties uch as 
sensitivity to Ca?+, preference for phospholipid co-fac- 
. ..-I ,rr,:.., c ’ tGi% arru oruurr~ LO ChffXCiZ i;iGZii; SiiLuSucrrbzi ~Atlj,Ziiid C-,.*-J-. l-1 
with their different subcellular localization [24]. Thus, 
PKC-a has been reported to associate with cytoskcletal 
components in several cell lines [34,35] and PKC-E is 
Table I 
Effects of PKC-isoform-specitic antibodies on extension of processes 
in Stl-SY5Y cells 
Additions Cells with ncuritcs 








Anti-PKC-a + a-ant&n 
a-antigen 
Anti-PKC-& + &-antigen 
.s-antigen 
Anti-PKC-o + -E 
Anti-PKC-rz + -E + a- and 
100.0 + 21.3 
241.3 + 38.7 O.Ool 
141.3 !I 30.6 n.5. 
151.3 t 43.7 n.s. 
lO4,cr r 28.0 
233.3 + 41.3 0.;; 
162.7 h 33.3 ns. 
84.0 f 12.0 ns. 
137.3 + 25.3 n.5. 
98.7 t- 8.0 n.s. 
368.0 1: 40.0 O.oM)l 
s-anligens 136.0 4 29.3 n.5. 
SH-SYSY cells were permeabilizcd and loaded with I:200 dilution of 
PKC-isoform-spccificanlibodies as described in scotion 2. PKC-a and 
PKC-& antigen peptides wcrc used to pre-absorb the scra. Data arc 
means & SD. of data pooled from two separate experimcnte. Expcri- 
ments were rcpcatcd more than 8 times with similar rcs~la, except for 
some variability in the basal number of cells bearing ncuritcs. Data 
are expressed as preenlag:cs of controls to offset the variable baselinc 
values. The pcrccntagc of ncurhc-lxaring eells in untreated cultures 
(no antiserum in the pcrmeabilization protocol) was 7.5 f 1.6%. 
93 
Volume 297, number 1,2 FEBS LETTERS February 1991 
nearly exclusively localized in the membranes and pro- 
cesses in §H-SYSY cells [24]. 
In conclusion, the data presented here show that in 
neuroblastoma cells expressing multiple isoforms of 
PKC, it is the a and E isoforms that are selectively 
involved in the control of the acquisition of a mor- 
phologically differentiated phenotype. 
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